214 related articles for article (PubMed ID: 27485514)
1. A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.
Mack E; Stabla K; Riera-Knorrenschild J; Moll R; Neubauer A; Brendel C
BMC Cancer; 2016 Aug; 16():585. PubMed ID: 27485514
[TBL] [Abstract][Full Text] [Related]
2. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.
de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW
Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782
[TBL] [Abstract][Full Text] [Related]
3. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection.
Ibrahem S; Seth R; O'Sullivan B; Fadhil W; Taniere P; Ilyas M
Int J Exp Pathol; 2010 Dec; 91(6):500-5. PubMed ID: 21199003
[TBL] [Abstract][Full Text] [Related]
5. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.
Sundström M; Edlund K; Lindell M; Glimelius B; Birgisson H; Micke P; Botling J
BMC Cancer; 2010 Dec; 10():660. PubMed ID: 21122130
[TBL] [Abstract][Full Text] [Related]
6. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
Vaughn CP; Zobell SD; Furtado LV; Baker CL; Samowitz WS
Genes Chromosomes Cancer; 2011 May; 50(5):307-12. PubMed ID: 21305640
[TBL] [Abstract][Full Text] [Related]
7. QIAGEN Therascreen KRAS RGQ Assay, QIAGEN KRAS Pyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis of KRAS Mutations in Tumor Specimens.
Alqahtani QM; Crowley A; Rapp S; Cushman-Vokoun AM
Lab Med; 2016 Feb; 47(1):30-8. PubMed ID: 26732779
[TBL] [Abstract][Full Text] [Related]
8. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
9. Clinical Evaluation of IntelliPlex™ KRAS G12/13 Mutation Kit for Detection of KRAS Mutations in Codon 12 and 13: A Novel Multiplex Approach.
Chen CL; Chen CK; Ho CL; Chi WM; Yeh CH; Hu SP; Friebe P; Palmer S; Huang CS
Mol Diagn Ther; 2019 Oct; 23(5):645-656. PubMed ID: 31347028
[TBL] [Abstract][Full Text] [Related]
10. Sensitive High-Resolution Melting Analysis for Screening of KRAS and BRAF Mutations in Iranian Human Metastatic Colorectal Cancers.
Karbalaie Niya MH; Basi A; Koochak A; Safarnezhad Tameshkel F; Rakhshani N; Zamani F; Imanzade F; Rezvani H; Adib Sereshki MM; Sohrabi MR
Asian Pac J Cancer Prev; 2016 Dec; 17(12):5147-5152. PubMed ID: 28122448
[TBL] [Abstract][Full Text] [Related]
11. KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13.
Bihl MP; Hoeller S; Andreozzi MC; Foerster A; Rufle A; Tornillo L; Terracciano L
Diagn Mol Pathol; 2012 Mar; 21(1):14-23. PubMed ID: 22306671
[TBL] [Abstract][Full Text] [Related]
12. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
Krol LC; 't Hart NA; Methorst N; Knol AJ; Prinsen C; Boers JE
Eur J Cancer; 2012 May; 48(7):1108-15. PubMed ID: 22446020
[TBL] [Abstract][Full Text] [Related]
13. A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas.
Jancik S; Drabek J; Berkovcova J; Xu YZ; Stankova M; Klein J; Kolek V; Skarda J; Tichy T; Grygarkova I; Radzioch D; Hajduch M
J Exp Clin Cancer Res; 2012 Sep; 31(1):79. PubMed ID: 22995035
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography.
Karim B; Florence C; Kamel R; Nadia K; Ines O; Raja M; Sarra BJ; Florent S; Amel BA
Cancer Biomark; 2010-2011; 8(6):331-40. PubMed ID: 22072121
[TBL] [Abstract][Full Text] [Related]
15. Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.
Dudley J; Tseng LH; Rooper L; Harris M; Haley L; Chen G; Gocke CD; Eshleman JR; Lin MT
Arch Pathol Lab Med; 2015 Feb; 139(2):211-8. PubMed ID: 25611103
[TBL] [Abstract][Full Text] [Related]
16. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
17. Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.
Harlé A; Busser B; Rouyer M; Harter V; Genin P; Leroux A; Merlin JL
Virchows Arch; 2013 Mar; 462(3):329-35. PubMed ID: 23400679
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two different screening methods for the KRAS mutation in colorectal cancer.
Er TK; Chang YS; Yeh KT; Chang TJ; Chang JG
Clin Lab; 2010; 56(5-6):175-86. PubMed ID: 20575464
[TBL] [Abstract][Full Text] [Related]
19. Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer.
Kristensen LS; Kjeldsen TE; Hager H; Hansen LL
BMC Cancer; 2012 Nov; 12():548. PubMed ID: 23173730
[TBL] [Abstract][Full Text] [Related]
20. Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.
Chretien AS; Harlé A; Meyer-Lefebvre M; Rouyer M; Husson M; Ramacci C; Harter V; Genin P; Leroux A; Merlin JL
Cancer Med; 2013 Feb; 2(1):11-20. PubMed ID: 24133623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
